Clinical Trial Update: Use of UC-MSCs for COVID-19 Patients [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 clinical trial evaluating umbilical cord-derived mesenchymal stem cells (UC-MSCs) for COVID-19-related ARDS.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Distress Syndrome

Drugs mentioned

• UC-MSCs (umbilical cord-derived mesenchymal stem cells)

Snippet

Sponsor: Camillo Ricordi | Conditions: Corona Virus Infection, ARDS | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-12-06